CAS 1622849-58-4

(S)-5-Benzyl-N-(5-Methyl-4-Oxo-2,3,4,5-Tetrahydrobenzo[b][1,4]Oxazepin-3-Yl)Isoxazole-3-Carboxamide

CAS : 1622849-58-4

(S)-5-Benzyl-N-(5-Methyl-4-Oxo-2,3,4,5-Tetrahydrobenzo[b][1,4]Oxazepin-3-Yl)Isoxazole-3-Carboxamide

Degré de pureté : 99%

Masse moléculaire : 377.39g/mol

Ref: 54-OR1024340

GSK481

CAS : 1622849-58-4

GSK481

Degré de pureté : ≥98%

Masse moléculaire : 377.39g/mol

Ref: 54-BUP10003

GSK481

CAS : 1622849-58-4

GSK481 (GSK'481) is a RIP1(Receptor Interacting Protein Kinase1) inhibitor. Inhibition of RIP1 has been shown to hinder cell necrotic death.

Formule : C₂₁H₁₉N₃O₄

Degré de pureté : 98.97%

Couleur et forme : Solid

Masse moléculaire : 377.39

Ref: TM-T6852

GSK481

CAS : 1622849-58-4

GSK481 is an investigational therapeutic product, which is a pharmaceutical compound developed by the global healthcare company GlaxoSmithKline (GSK). The source of this compound derives from extensive medicinal chemistry and drug development processes aimed at addressing specific molecular targets. GSK481 functions through a targeted mode of action that modulates particular biochemical pathways implicated in disease pathophysiology. The compound's mechanism involves binding to specific molecular targets to inhibit or modify their activity, thereby altering the progression of the disease process.

Formule : C₂₁H₁₉N₃O₄

Degré de pureté : Min. 95%

Masse moléculaire : 377.39 g/mol

Ref: 3D-XPC84958